

24th

ECCMID

Barcelona, Spain
10 – 13 May 2014



ESCMID

EUROPEAN SOCIETY OF CLINICAL
MICROBIOLOGY AND INFECTIOUS DISEASES



Why are some carbapenemases successful?



Rafael Cantón

Hospital Universitario Ramón y Cajal
SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA



Departamento de
Microbiología II
Universidad
Complutense. Madrid



Why are some carbapenemases successful?

- What have we learned from **ESBLs**, particularly from **CTX-Ms**?

- Emergence of specific ESBLs in different and distant parts of the world and latter spread and dominance of other ESBLs

- 1989-2000	FEC-1	Japan	CTX-M-9	Spain
	CTX-M-1	Germany	CTX-M14	Korea
	CTX-M-2	Argentina	CTX-M-15	India
	Toho-1	Japan	CTX-M-8	Brazil
	CTX-M-3	Poland	CTX-M-25	Canada

- 2000 - ... Globalization of specific β -lactamases (CTX-M-15, ...)

Cantón, Gonzalez-Alba, Galán. *Frontiers Microbiol* 2012; 3:1-19

- Different evolutionary trajectories following different selective forces also affecting the spectrum of different CTX-Ms

- from cefotaximases to cetaximases/ceftazidimases


Novais et al. *Antimicrob Agents Chemother* 2008;52:2377-82

Novais et al. *PlosPathogen* 2010; 6, e1000735


Why are some carbapenemases successful?

- What did we learn with **ESBLs** and particularly with **CTX-Ms**?
 - different genetic environments of *bla*_{CTX-M} genes participating in the mobilization, spread and maintenance of these genes
 - ISEcp1, ISCR1, IS10, IS26, ...
Lartige et al. FEMS Microbiol Lett 2004;234:201-7
 - “epidemic resistance plasmids” from different incompatibility groups harbouring different resistance/virulence traits
 - IncFII, IncN, IncI1, IncL/M, IncK, IncHI2 ...
 - *qnr*, *aac(6')Ib-cr*, ...
Caratoli A. AAC 2009; 53:2227-38, Cantón et al. Frontiers Microbiol 2012; 3:1-19
 - dispersion of multi-drug resistant and virulent **high-risk clones**
 - *E. coli* (ST38, ST131, ST405 ...), *K. pneumoniae* (ST11, ST15, ...)
Cantón et al. Frontiers Microbiol 2012; 3:1-19

Hierarchical complexity of *bla*_{CTX-M} genes within genetic structures and bacterial clones




B2 O:25:H4ST131
E. coli



From clones to high risk clones (HiRiCs)


ESBL producing *K. pneumoniae*

Hospital Ramón y Cajal (Madrid, Spain 1989 to 2000)



- Ephemeral clones
- Persistent clones

From clones to high risk clones (HiRiCs)



Baquero F. Nat Rev Microbiol 2004; 2:510-8

Baquero, Coque, Cantón. ASM News 2003; 69: 547-51
Cantón, Coque, Baquero. Curr Opin Infect Dis 2003; 16:315-25
Cantón, Ruiz-Garbajosa Curr Opin Pharmacol 2011; 11:477-85

High risk clones (HiRiCs)


- **Bacterial clones associated with**
 - **antimicrobial resistance mechanism** of critical clinical importance
 - ability to efficiently **colonize** human hosts during **long periods** of time
 - ability to **be transmitted with high efficiency** among patients
 - ability to produce **severe or invasive infections**
- Major role in the **spread of resistance**
- Risk lying in their
 - tenacity and flexible ability to accumulate and exchange resistance and virulence genes

TROCAR FP7 Health EU project

Willems et al. FEMS Microbiol Rev 2011; 35:872-900
Woodford et al. FEMS Microbiol Rev 2011; 35:736-55
Baquero & Coque. FEMS Microbiol Rev 2011 35:705

Why are some carbapenemases successful?

- Do we have similar situation with carbapenemase producers than with ESBL producers?


- 
- complex group of enzymes
 - chronological emergence in different geographic areas
 - different population structure and dispersion models
 - dispersion and predominance of high-risk clones
 - polyclonal situation
 - insertion of *bla*_{carba} genes in well adapted plasmid
 - variable virulence traits (even with less virulence)
 - different susceptibility profile (multiresistance phenotype)

Carbapenemases

Molecular class ¹ (Functional Group ²)	Enzymes	Inhibited by		ATM	Organisms	Gene	Relevance
		CLA	EDTA				
A (2f)	Sme-1 to -3, IMI-1 to -3, NmcA, SFC-1	±	-	R	<i>S. marcescens</i> <i>E. cloacae</i>	Ch	±
	KPC-2 to -15	±	-	R	<i>Enterobacteriaceae</i> <i>P. aeruginosa</i> <i>A. baumannii</i>	PI	+++ +
	GES-1 to 23	+	-	S/R	<i>Enterobacteriaceae</i> <i>P. aeruginosa</i> <i>A. baumannii</i>	PI	+
B (3)	IMP-1 to -45, VIM-1 to -39, NDM-1 to -10, SPM-1, SIM, GIM, IND-1 to -15, AIM, DIM, KHM, ...	-	+	S	<i>Enterobacteriaceae</i> <i>P. aeruginosa</i> other GNNFB	PI/Ch	± / +++
D (2df)³	OXA-23 group (-23,-27 -49) OXA-24 group (-24,-25,-26,-40,-72) OXA-40 group (-40, -143) OXA-58 OXA-48 group (-48,-162,-163,-181, -204,-232)	±	- ⁴	S	<i>A. baumannii</i> <i>P. aeruginosa</i> <i>Enterobacteriaceae</i>	PI/Ch	++

1: Ambler classification. 2: Bush, Jacoby & Medeiros classification; 3: only class D carbapenemases representative of different groups have been included; 4: some OXA enzymes may be slightly inhibited by EDTA. CLA: clavulanate; EDTA: ethylenediaminetetraacetic ac; ATM: aztreonam; Ch: Chromosomal; PI: plasmid

Emergence of successful carbapenemases in Enterobacteriaceae




Carbapenemases: population structure

- Emergence and dispersion of specific clones associated with
 - specific carbapenemases (**clonal spread**)
 - ST258 *K. pneumoniae* and KPC-2
 - different carbapenemases (**polyclonal spread**)
 - ST15 *K. pneumoniae* and OXA-48 and VIM-1
 - ST14 *K. pneumoniae* and NDM-1, KPC and ST14
 - ST131 *E. coli* and KPC-2, VIM-1 and NDM-1
 - ST101 *E. coli* and KPC-2 and NDM-1
- Acquisition of (new) carbapenemases in pre-existing carbapenemase clones
 - clones coproducing different carbapenemases

Also expressing
ESBLs and other
resistance mechanisms

Acquisition
within the
clonal local
pool?


World wide dissemination of KPC-Enterobacteriaceae



Muñoz-Price et al. Lancet Infect Dis 2013; 13:785-96


- Few *K. pneumoniae* clones associated with bla_{KPC} dissemination:
 - high-risk clones (ST258)
 - clones belonging to the same clonal complex of ST258 (ST11, 14,...)
 - minor clones (singletons) based in local epidemiology

Dispersion of KPC-K. pneumoniae high-risk clone ST258



- Cross border dissemination (*K. pneumoniae* ST258) from endemic areas


World wide dissemination of MBL-Enterobacteriaceae



- In different Enterobacteriaceae, including *E. coli*, *K. pneumoniae*, *Enterobacter* spp., (also in *P. aeruginosa* and *A. baumannii*)
 - high-risk clones (ST11, ...) and polyclonal situation

Dissemination of NDM-Enterobacteriaceae

NDM-1




Rolain et al. Clin Microbiol Infect 2010;16:1699-701
Struelens et al. Eurosurveillance 2010; 15 18 nov

Carbapenemase producing Enterobacteriaceae

OXA-48

- First identified in *K. pneumoniae* in Istanbul (Turkey) in 2003
- Extensively reported as a source of *K. pneumoniae* nosocomial outbreaks
- Well disseminated in the Mediterranean area and in western EU countries (*cross-border dissemination*)



OXA-48 and Enterobacteriaceae clones

- **Polyclonal structure**

- different clones in different Enterobacteriaceae species, including high-risk clones and non-widespread clones

Poirel et al. J Antimicrob Chemother 2012;67:1597-606

Potron et al. Euro Surveill 2013; 18(31) doi:pii: 20549

- Dispersion of **specific clones**: ST395, ST101 *K. pneumoniae*

- hospital outbreaks in different countries
- spread in the community

Potron et al. Clin Microbiol Infect 2011; 17:E24-6

Pitart et al. Antimicrob Agents Chemother 2011; 55: 4398-401

- Emergence in **widespread clones** *E. coli* O25b:H4 ST131

- Ireland, UK
- absence of other β -lactamases (ESBLs, OXA, ...)

Morris et al. Antimicrob Agents Chemother 2012; 56:4030-1


Dimou et al. J Antimicrob Chemother 2012; 67:1660-5

- **Cross border dissemination** from endemic areas


Cantón et al. Clin Microbiol Infect 2012; 18:413-31

OXA-48 and Enterobacteriaceae clones

- Polyclonal structure with over-representation of specific clones



Klebsiella pneumoniae population snapshot



Most carbapenemase producers are clustered in the same clonal complex (CC37) irrespective of the carbapenemase

Are these clones more virulent?
Are these clones more persistent?

Carbapenemase producing *K. pneumoniae*

Are these clones producing carbapenemases more virulent?

- Most studies has been performed with KPC-producers
 - No specific virulence factors associated with these clones
 - Low impact of carbapenemase expression on virulence ^{1,2}
- In general, low virulence of KPC-isolates in
 - mouse lethality model due to the absence of known virulence factors (K1, K2, and K5 capsular polysaccharides, *rmpA* aerobactin)³
 - nematode (*Caenorhabditis elegans*) killing assay due to the absence of siderophores genes⁴
- Higher virulence of ST258 and its single (ST11) and double (ST277) locus variants than non-ST258 clones (ST377, ST378)⁴



¹Nordmann et al. LID 2009; 9:228-36; ²Siu et al. MDR 2012; 18:380-4

³Siu et al. MDR 2012; 380-4 ⁴Lavigne et al. Plos One 2013; 8:e67847

Carbapenemase producing *K. pneumoniae*

Are these clones producing carbapenemases more virulent?

- Lower mortality of KPC-(+) vs KPC-(-) blood isolates in the *Galleria mellonella* insect model but discrepant with clinical results¹
- High susceptibility of a bla_{KPC-2} InCFIIk-ST258 strain circulating in Greece to serum killing and rapidly phagocytosed²
- ST258 strains carrying bla_{KPC-3} are less virulent than those with bla_{KPC-2} ³




¹MaLaughlin et al. BMC Infect Dis 2014; 14:31; ²Tzouveleakis et al. AAC 2013 57:5144-46;

³Diago-Navarro et al. JID 2014; Mar 14 [Epub ahead of print]

Carbapenemase producing *K. pneumoniae*

Are these clones producing carbapenemases more persistent?

- Only 10% of KPC-ST258 colonized patients develops infections^{1,2}
- Risk factor of infection: previous colonization³
- Prolonged in patient from LTCF⁴
- The majority of patient might spontaneously decolonized within 6 months after hospital discharge⁵




¹Borer et al. AJIC 2012; 40:421-5; ²Schechner et al. CMI 2013; 19:451-6; ³Gasink et al ICHE 2009; 30: 1180-5;

⁴Feldman et al. Clin Microbiol Infect 2012; 19:E190-6; ⁵Lübbert et al. Am J Infect Control 2014; 42:376-80

*bla*_{KPC} genes and plasmids

Are these traits associated with plasmids?


- *bla*_{KPC} in highly transferable plasmids of different sizes
 - mostly common scaffolds and derived well-known plasmids from *K. pneumoniae* (KPN3 and KPN4)
 - different incompatibility groups (FII, L/M, N, A/C, R, X, ColE1, I2, ...)



Leavitt et al. AAC 2010; 54:4493-6; García-Fernández et al. AAC 2012;56:2143-5
Cheng et al. AAC 2013;1542-5; Cheng et al. AAC 2013; 29 July

*bla*_{OXA-48} gene and plasmids

- Dissemination mainly associated with **IncL/M** plasmids (Turkey, Libano, Australia, Spain, Belgium, ...) but also with IncA/C and IncF



Poirel et al. AAC 2012; 56:559-62; Espedido Plos One 2013; 8:e59920


- the *bla*_{OXA-48} gene within in a composite transposon, Tn1999, inserted into the *tir* gene, encoding a transfer inhibition protein
 - increased transfer frequency

Potron et al. Antimicrob Agents Chemother 2014; 58:467-71

Carbapenemase producing isolates

Co-resistance

- Antibiotic susceptibility of carbapenemase producing isolates (n=81)



Why are some carbapenemases successful?

Conclusions

- Resemblance with ESBL producers (emergence/dissemination)
- Dispersion associated with clonal (high-risk clones) and polyclonal situations
- Associated carbapenemase producing high-risk clones are
 - less virulent than susceptible isolates
 - high capacity to colonize and persist over time
- Presence of *bla*_{carbapenemase} genes in ancient well adapted plasmids with highly transferable activity
- Co-resistance might play a role on selection and persistence

Acknowledgements

Fernando Baquero
Rafael Cantón
Teresa M. Coque
Tania Curiao
Juan Carlos Galán
Desirée Gijón
Jose M. Gonzalez Alba
María Isabel Morosini
Ana Moreno
Patricia Ruiz Garbajosa
Marta Tato
Arancha Valverde



Hospital Ramón y Cajal



Madrid

Antonio Oliver,
Luisa Peixe, Angela Novais
Patrice Nordmann / Laurent Poirel

Comunidad de Madrid: CAM 2000-0049
Fondo de Investigaciones Sanitarias:
FIS PI 2043-2002; FIS 01/412
FIS 040162; REIPI C03/14, CIBER-ESP

Ministerio de Ciencia y Tecnología
SAF 2003-09285

European Commission
LSHM-CT-2003-503335; -CT-2008-223031
Fundación para la Investigación Biomédica
de Hospital Ramón y Cajal (FIBIO)
Fundación de Ciencias Microbianas (FCM)



SEVENTH FRAMEWORK
PROGRAMME

trocar

TRANSLATIONAL RESEARCH ON COMBATING
ANTIMICROBIAL RESISTANCE



R-GNOSIS

RESISTANCE IN GRAM-NEGATIVE ORGANISMS:
STUDYING INTERVENTION STRATEGIES

24th

ECCMID

Barcelona, Spain
10 – 13 May 2014



ESCMID

EUROPEAN SOCIETY OF CLINICAL
MICROBIOLOGY AND INFECTIOUS DISEASES



Why are some carbapenemases successful?



Rafael Cantón

Hospital Universitario Ramón y Cajal
SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA



Departamento de
Microbiología II
Universidad
Complutense. Madrid

